Last updated: March 5, 2026
What is the drug identified by NDC 70069-0586?
NDC 70069-0586 corresponds to Riluzole Tablets, 50 mg, manufactured by H. Lundbeck A/S. It is approved for the treatment of amyotrophic lateral sclerosis (ALS).
What is the current market landscape?
Market size and demand
- Prevalence of ALS: Estimated at 2-3 per 100,000 people globally. In the U.S., approximately 6,000 new cases are diagnosed annually.
- Market penetration: Riluzole remains the first-line therapy for ALS, with an estimated 50% market share among ALS treatments.
- Sales data: Estimated global sales in 2022: approximately $585 million, with the U.S. accounting for about 70% of revenue.
Competitive landscape
- Main competitors: Edaravone (Radicava) by Mitsubishi Tanabe Pharma.
- Market share of competitors: Edaravone holds approximately 35% of the ALS treatment market**.
- Pipeline activity: Limited additional approved therapies for ALS, maintaining riluzole's dominance.
Regulatory environment
- FDA status: Approved since 1995.
- Pricing regulation: No direct regulation but subject to insurance negotiations and formulary considerations.
- Pricing trends: Historically, riluzole's price has remained stable but has shown slight increases aligned with inflation and manufacturing costs.
What are the price projections?
Current price point
- United States: Approximate wholesale acquisition cost (WAC) for 30 tablets of 50 mg is $900.
- Average retail price: About $1,200 with insurance, slightly higher than WAC.
Short-term projections (next 1-2 years)
- Price stability: Likely to remain steady barring new competitors or patent challenges.
- Potential increases: Up to 3% annually, driven by inflation and supply chain costs.
Long-term projections (3-5 years)
- Market saturation: Slight growth expected if new therapies fail to penetrate.
- Price adjustments: May vary between 0-5% annually, influenced by:
- Emergence of generic versions post-patent expiry.
- Pricing pressures from insurers.
- Market expansion via broader indications or increased diagnosis rates.
Impact of patent landscape
- Patent expiration: Patents expire around 2024-2025, opening door for generics.
- Generic entry impacts:
- Price reductions by 40-60% expected within the first year post-generic launch.
- Competition could lower average prices to $500-$700 per course.
Price sensitivity factors
- Insurance coverage: Can significantly influence out-of-pocket costs.
- Formulary placement: Tier placement impacts patient cost-sharing.
- Manufacturing costs: Advances in biosimilars may further reduce prices.
Summary table: Price trends and market factors
| Timeframe |
Price trend |
Key factors |
Notes |
| 2023-2024 |
Stable with slight increase |
Inflation, supply chain costs |
No new entrants, patent protections intact |
| 2024-2025 |
Possible decline |
Patent expiry, generic entry |
Prices could decrease by 40-60% |
| 2025-2028 |
Stabilization or further reduction |
Competition, market saturation |
Generic competition influences prices |
Key takeaways
- Riluzole (NDC 70069-0586) is a market leader for ALS, with high and stable demand.
- The recent patent expiry prospects between 2024-2025 will likely lead to substantial price drops.
- Short-term pricing stability is expected, but long-term projections foresee potential reductions due to generic competition.
- Market growth depends on ALS diagnosis rates and regulatory/payer dynamics.
- Price discounts from generics could lower average treatment costs by up to 50%.
FAQs
1. When will generics for riluzole become available?
Patent protections are expected to expire around 2024-2025, leading to generic versions entering the market shortly after.
2. How much can prices decrease with generic entry?
Generic competition typically reduces prices by 40-60% within the first year of launch.
3. What are the main competitors to riluzole?
Edaravone (Radicava) is the primary alternative, with a smaller market share and similar efficacy.
4. Are there any upcoming regulatory changes that may impact pricing?
No significant regulatory changes are announced; pricing remains influenced mainly by patent status and competition.
5. How do insurance companies influence riluzole prices?
Insurance negotiations and formulary placement can substantially affect patient out-of-pocket costs and overall drug pricing.
References
- FDA. (2022). Riluzole — Product information. Retrieved from [FDA website].
- IQVIA. (2022). U.S. prescription drug market data.
- EvaluatePharma. (2022). Global Pharmaceutical Market Outlook.
- American Academy of Neurology. (2022). ALS prevalence and treatment guidelines.
- Pharma Intelligence. (2023). Generic drug market entry and pricing analysis.
[1] U.S. Food and Drug Administration. (2022). Riluzole (Rilutek) approval history.
[2] IQVIA. (2022). National Prescription Audit.
[3] EvaluatePharma. (2022). World Preview 2022.
[4] American Academy of Neurology. (2022). ALS treatment updates.
[5] Pharma Intelligence. (2023). Generic competition and impact on drug prices.
